Clinical Trial Update: A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma [NA]

View source ↗

Summary

A clinical trial protocol evaluating Firsekibart, Tislelizumab, and Lenvatinib in unresectable hepatocellular carcinoma with TP53 mutation; the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Firsekibart
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tongji Hospital | Conditions: HCC - Hepatocellular Carcinoma, TP53 Gene Mutation | NA | Status: NOT_YET_RECRUITING